Among patients with carcinoembryonic antigen levels < 2.12 ng/mL (Table 2), EGFR mutations were associated with age (P < 0.001), tumour size (P < 0.001), histology (P < 0.001), and stage (P < 0.001). This evidence concerns the gene EGFR and neoplasm.